ATE350660T1 - Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression - Google Patents

Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Info

Publication number
ATE350660T1
ATE350660T1 AT02700679T AT02700679T ATE350660T1 AT E350660 T1 ATE350660 T1 AT E350660T1 AT 02700679 T AT02700679 T AT 02700679T AT 02700679 T AT02700679 T AT 02700679T AT E350660 T1 ATE350660 T1 AT E350660T1
Authority
AT
Austria
Prior art keywords
integrin expression
angionegesis
studying
inhibition
effect
Prior art date
Application number
AT02700679T
Other languages
English (en)
Inventor
Naoto Ono
Taro Senba
Naoko Hata
Yasuhiro Funahashi
Toshiaki Wakabayashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE350660T1 publication Critical patent/ATE350660T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02700679T 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression ATE350660T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21

Publications (1)

Publication Number Publication Date
ATE350660T1 true ATE350660T1 (de) 2007-01-15

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06013455T ATE412895T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
AT02700679T ATE350660T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06013455T ATE412895T1 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression

Country Status (11)

Country Link
US (1) US7122318B2 (de)
EP (2) EP1742052B1 (de)
JP (1) JP4255285B2 (de)
KR (1) KR20030080013A (de)
CN (2) CN100384482C (de)
AT (2) ATE412895T1 (de)
AU (1) AU2002233677B2 (de)
CA (1) CA2438427C (de)
DE (2) DE60217300T2 (de)
ES (2) ES2317368T3 (de)
WO (1) WO2002066073A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412895T1 (de) 2001-02-21 2008-11-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression
US20040235866A1 (en) * 2001-09-05 2004-11-25 Takahisa Hanada Lymphocytic activation inhibitor and remedial agent for autoimmune disease
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
EP3873605B1 (de) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Verbindungen zur inhibierung von alpha4-beta7-integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007276A1 (en) * 1993-09-10 1995-03-16 Eisai Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
ES2160949T3 (es) * 1996-03-29 2001-11-16 Searle & Co Derivados de fenilen-sulfonamida sustituidos en meta.
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
AU724216B2 (en) * 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
MXPA02007249A (es) 2000-02-03 2002-12-09 Eisai Co Ltd Inhibidor de la expresion de integrina.
ATE412895T1 (de) 2001-02-21 2008-11-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der wirkung eines angiogenese-hemmers unter vermittlung durch hemmung der integrin-expression

Also Published As

Publication number Publication date
CA2438427C (en) 2011-04-12
EP1362601A1 (de) 2003-11-19
DE60229676D1 (de) 2008-12-11
EP1362601A4 (de) 2005-07-06
ES2317368T3 (es) 2009-04-16
JPWO2002066073A1 (ja) 2004-06-17
EP1742052B1 (de) 2008-10-29
CA2438427A1 (en) 2002-08-29
US20040132783A1 (en) 2004-07-08
DE60217300D1 (de) 2007-02-15
EP1742052A1 (de) 2007-01-10
ES2280502T3 (es) 2007-09-16
CN1620313A (zh) 2005-05-25
EP1362601B1 (de) 2007-01-03
CN101025419A (zh) 2007-08-29
JP4255285B2 (ja) 2009-04-15
ATE412895T1 (de) 2008-11-15
HK1059038A1 (en) 2004-06-18
EP1362601B8 (de) 2007-02-28
AU2002233677B2 (en) 2005-01-06
WO2002066073A1 (en) 2002-08-29
US7122318B2 (en) 2006-10-17
HK1099363A1 (en) 2007-08-10
DE60217300T2 (de) 2007-10-04
CN100384482C (zh) 2008-04-30
KR20030080013A (ko) 2003-10-10

Similar Documents

Publication Publication Date Title
ATE350660T1 (de) Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression
ATE404890T1 (de) Verfahren und vorrichtung zur schnellen tomographischen messung der elektrischen leitfähigkeitsverteilung in einer probe
WO2004113912A8 (en) System and method for determining a temperature during analysis of biological fluid
ATE207609T1 (de) Verfahren und vorrichtung zur überprüfung eines sensors
ATE539674T1 (de) Nichtinvasive blutanalyse durch optische sondierung der venen unter der zunge
DE69920940D1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
ATE427067T1 (de) Verfahren zur detektierung von temperaturanderungen
ATE265177T1 (de) Vorrichtung, computersystem und computerprogramm zur bestimmung eines kardiovasculären parameters
ATE551950T1 (de) Verfahren zur messung von spannungszuständen eines materials und seine anwendung
ATE368229T1 (de) Diagnostischer test zur bestimmung der konzentration einer transienten proteolytischen aktivität in zusammengesetzten biologischen medien
Lawson et al. Tear strength of five elastomeric impression materials at two setting times and two tearing rates
ATE446561T1 (de) Sensoranordnung
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
ATE313788T1 (de) Feuchtigkeitsfühler mit kapazitivem feuchte- messelement und verfahren zur erfassung der luftfeuchtigkeit
ATE335434T1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
ATE448496T1 (de) Verfahren und einrichtung zur hydrometeor- detektion
DE602004024484D1 (de) Vorrichtung und Verfahren zum Messen der Parameter bei Prüfungen während des Fluges eines Luftfahrzeug
ATE469347T1 (de) Verfahren und vorrichtung zum testen eines objekts mit ultraschall
ATE472427T1 (de) Verfahren zur messung eines drucks
DE60203524D1 (de) Verfahren zur messung des arteriolendrucks
EP4613181A4 (de) Tragbare vorrichtung und verfahren zur verbesserung der genauigkeit von messungen eines physiologischen index
ATE295797T1 (de) Verfahren zum erzeugen eines einen lagerschaden an einem achslager angebenden alarmsignals
DE50009357D1 (de) Verfahren zur bestimmung der belastbarkeit eines menschen
ATE463671T1 (de) Verfahren und vorrichtung zur messung der einspritzmenge und der einspritzrate eines einspritzventils für flüssigkeiten
EP1661991A4 (de) Mit hepatozellulärem karzinom assoziiertes gen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1362601

Country of ref document: EP